SHPH · Shuttle Pharmaceuticals Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Our ability to continue as a going concern is dependent upon our ability to continue to successfully raise additional equity or debt financing to allow us to fund ongoing operations, and commercialize, fund milestone and contingent payments due under the APA, and market our Molecule.ai platform in order to generate revenues. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements contained in the report are issued.”View the 10-Q filed May 15, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 11, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jun 11, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SHPH
this stock
Shuttle Pharmaceuticals Holdings, Inc.
|
$2.05M | — | — | — | 6.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.15B | +16.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.01B | -9.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.94B | +16.5% | +4.3% | 60.4 | 3.2% |
|
HLN
Haleon plc
|
$40.55B | -8.8% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 11, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SHPH | +1.2% | -16.6% | — | +5.1% | — |
| SPY | -1.0% | -1.9% | +14.9% | -1.2% | +11.1% |
| vs SPY | +2.1% | -14.7% | — | +6.3% | — |